Loyal
Last verified 2026-05-25. JSON
The funding figures on this page are attributed, not sourced: a publisher is on record but no document URL is. How we mark provenance.
| Total raised | $250.0Mattributed |
|---|---|
| Latest round | series-c, $100.0M, 2026-02-01attributed |
| Founded | 2019 |
| Headquarters | San Francisco, USA |
| Industry | biotech |
| Stage | series-b+ |
| Website | loyalfordogs.com |
Loyal is a veterinary biotech company developing drug therapies to extend the healthy lifespan of dogs, pursuing the first FDA-approved longevity drugs for companion animals. Its lead compound LOY-001 targets IGF-1 signalling, the same pathway associated with lifespan differences between large and small dog breeds.
Funding rounds
| Date | Round | Amount | Lead |
|---|---|---|---|
| 2026-02-01 | series-c | $100.0M | khosla |
Detected tech stack
unknown
Provenance
| Fact | Status | Basis |
|---|---|---|
| Series C, $100.0M | attributed | vc-portfolio named as publisher. No document URL on file. |
| Total raised $250.0M | attributed | vc-portfolio named as publisher. No document URL on file. |
| Company existence | self-reported | loyalfordogs.com, read 2026-05-25 |
| Description | self-reported | loyalfordogs.com, read 2026-05-25 |
Nothing on this page is sourced yet. A sourced fact links to a document that states it.
Change history
No change recorded since records began on 2026-09-24.